Prima BioMed Ltd Company Profile (NASDAQ:PBMD)

About Prima BioMed Ltd (NASDAQ:PBMD)

Prima BioMed Ltd logoPrima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PBMD
  • CUSIP: N/A
  • Web: www.primabiomed.com.au
Capitalization:
  • Market Cap: $51.1 million
  • Outstanding Shares: 20,730,000
Average Prices:
  • 50 Day Moving Avg: $2.44
  • 200 Day Moving Avg: $2.05
  • 52 Week Range: $0.51 - $3.26
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.85
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $1.56 million
  • Price / Sales: 32.76
  • Book Value: $1.10 per share
  • Price / Book: 2.24
Profitability:
  • EBIDTA: ($6,420,000.00)
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 14.75%
  • Quick Ratio: 14.75%
Misc:
  • Average Volume: 49,167 shs.
  • Beta: 1.83
  • Short Ratio: 1.48
 

Frequently Asked Questions for Prima BioMed Ltd (NASDAQ:PBMD)

What is Prima BioMed Ltd's stock symbol?

Prima BioMed Ltd trades on the NASDAQ under the ticker symbol "PBMD."

Where is Prima BioMed Ltd's stock going? Where will Prima BioMed Ltd's stock price be in 2017?

4 brokerages have issued 1 year target prices for Prima BioMed Ltd's shares. Their forecasts range from $6.00 to $8.00. On average, they expect Prima BioMed Ltd's stock price to reach $6.75 in the next year. View Analyst Ratings for Prima BioMed Ltd.

What are analysts saying about Prima BioMed Ltd stock?

Here are some recent quotes from research analysts about Prima BioMed Ltd stock:

  • 1. According to Zacks Investment Research, "Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company's key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. " (5/3/2017)
  • 2. FBR & Co analysts commented, "On January 20, Prima BioMed announced the first patient dosing in the enlarged randomized portion of the AIPAC Phase IIb study with IMP321 in metastatic breast cancer (mBC). We think clinical progress with IMP321 is significantly under- appreciated, as the latest news is the seventh announcement since late November 2016. We also point to multiple value inflection points in 2017 that we think could be positive catalysts. PBMD also continues to make progress with its Phase I trial in melanoma (TACTI-mel), testing IMP321 plus a PD-1 blocking antibody (Keytruda), a hot immunotherapeutic anti-cancer strategy, and recently added a LAG-3 agonist antibody, IMP761, to its internal pipeline." (1/24/2017)

Are investors shorting Prima BioMed Ltd?

Prima BioMed Ltd saw a decrease in short interest in April. As of April 28th, there was short interest totalling 152,246 shares, a decrease of 6.5% from the April 13th total of 162,796 shares. Based on an average trading volume of 31,970 shares, the days-to-cover ratio is presently 4.8 days.

Who are some of Prima BioMed Ltd's key competitors?

How do I buy Prima BioMed Ltd stock?

Shares of Prima BioMed Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Prima BioMed Ltd stock cost?

One share of Prima BioMed Ltd stock can currently be purchased for approximately $2.47.

Analyst Ratings

Consensus Ratings for Prima BioMed Ltd (NASDAQ:PBMD) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (173.83% upside)

Analysts' Ratings History for Prima BioMed Ltd (NASDAQ:PBMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/28/2017HC WainwrightSet Price TargetBuy$8.00N/AView Rating Details
12/30/2016Maxim GroupReiterated RatingBuy$16.67 -> $7.00N/AView Rating Details
8/26/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Prima BioMed Ltd (NASDAQ:PBMD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Prima BioMed Ltd (NASDAQ:PBMD)
Current Year EPS Consensus Estimate: $-0.080 EPS
Next Year EPS Consensus Estimate: $-0.360 EPS

Dividends

Dividend History for Prima BioMed Ltd (NASDAQ:PBMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prima BioMed Ltd (NASDAQ:PBMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Prima BioMed Ltd (NASDAQ:PBMD)
Latest Headlines for Prima BioMed Ltd (NASDAQ:PBMD)
Source:
DateHeadline
nasdaq.com logoData From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference - Nasdaq
www.nasdaq.com - May 18 at 6:35 AM
feeds.benzinga.com logoData From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
feeds.benzinga.com - May 17 at 8:58 PM
americanbankingnews.com logoPrima BioMed Ltd (PBMD) Short Interest Down 6.5% in April
www.americanbankingnews.com - May 17 at 7:02 PM
americanbankingnews.com logoPrima BioMed (PBMD) Given Daily News Impact Rating of 0.22
www.americanbankingnews.com - May 4 at 11:17 AM
americanbankingnews.com logoPrima BioMed (PBMD) Getting Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 10:30 PM
americanbankingnews.com logoPrima BioMed (PBMD) Receiving Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 25 at 7:58 PM
americanbankingnews.com logoPrima BioMed Ltd (PBMD) Receives Buy Rating from FBR & Co
www.americanbankingnews.com - April 22 at 10:14 PM
americanbankingnews.com logoPrima BioMed (PBMD) Getting Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 22 at 1:59 PM
streetinsider.com logoPrima BioMed (PBMD) Granted Approval for Third Cohort of Ph1 Melanoma Trial - StreetInsider.com
www.streetinsider.com - April 21 at 9:08 AM
streetinsider.com logoPrima BioMed (PBMD) Granted Approval for Third Cohort of Ph1 Melanoma Trial
www.streetinsider.com - April 19 at 10:00 AM
finance.yahoo.com logoPrima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
finance.yahoo.com - April 19 at 9:59 AM
americanbankingnews.com logoPrima BioMed (PBMD) Receives News Impact Score of 0.48
www.americanbankingnews.com - April 19 at 8:07 AM
globenewswire.com logoPrima BioMed Receives A$492144 Tax Refund From Australian Government - GlobeNewswire (press release)
globenewswire.com - April 14 at 5:37 AM
americanbankingnews.com logoPrima BioMed (PBMD) Receives Daily News Sentiment Score of 0.02
www.americanbankingnews.com - April 13 at 6:15 PM
finance.yahoo.com logoPrima BioMed Receives A$492,144 Tax Refund From Australian Government
finance.yahoo.com - April 12 at 12:57 PM
americanbankingnews.com logoFBR & Co Analysts Give Prima BioMed Ltd (PBMD) a $6.00 Price Target
www.americanbankingnews.com - April 12 at 7:11 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for Prima BioMed Ltd's FY2017 Earnings (PBMD)
www.americanbankingnews.com - April 10 at 7:55 AM
americanbankingnews.com logoPrima BioMed Ltd (PBMD) Given a $6.00 Price Target at FBR & Co
www.americanbankingnews.com - April 7 at 10:07 PM
americanbankingnews.com logoFY2019 EPS Estimates for Prima BioMed Ltd Increased by FBR & Co (PBMD)
www.americanbankingnews.com - April 7 at 8:49 PM
americanbankingnews.com logoZacks: Prima BioMed Ltd (PBMD) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 6 at 8:04 AM
finance.yahoo.com logoPrima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
finance.yahoo.com - March 14 at 11:40 PM
finance.yahoo.com logoUSA Patent Grants for IMP321 in Cancer
finance.yahoo.com - March 1 at 10:17 AM
us.rd.yahoo.com logoFirst Half 2017 Operational Update
us.rd.yahoo.com - February 24 at 8:42 AM
investopedia.com logoPrima BioMed Bets Big on Cancer Drug IMP321 (PBMD)
www.investopedia.com - February 17 at 4:48 PM
investopedia.com logoPrima BioMed Bets Big on Cancer Drug IMP321
www.investopedia.com - February 17 at 4:48 PM
finance.yahoo.com logoPrima BioMed Receives ~A$860,000 Tax Credit Payment From French Government
finance.yahoo.com - February 13 at 12:02 AM
wsj.com logo[$$] Temasek, Others Plan to Sell Stake in Indonesian Retailer
www.wsj.com - February 2 at 1:47 AM
finance.yahoo.com logoPrima Biomed Initiates Randomized Study for Breast Cancer
finance.yahoo.com - January 23 at 9:37 AM
finance.yahoo.com logoPrima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
finance.yahoo.com - January 22 at 11:54 PM
finance.yahoo.com logoPrima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
finance.yahoo.com - January 19 at 11:49 PM
streetinsider.com logoPrima BioMed (PBMD) Regains NASDAQ Compliance - StreetInsider.com
www.streetinsider.com - January 18 at 8:45 AM
finance.yahoo.com logoPrima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
finance.yahoo.com - January 11 at 7:46 PM
rttnews.com logoWall Street Set For Mixed Opening
www.rttnews.com - January 6 at 4:53 AM
finance.yahoo.com logoPrima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody
finance.yahoo.com - January 2 at 6:56 PM
zacks.com logoPrima (PBMD) Reports Favorable Initial Melanoma Study Data
www.zacks.com - December 30 at 9:13 AM
finance.yahoo.com logo6:04 am Prima Biomed announced first clinical data from combination of IMP321 with ANTI-PD1; Database Safety Monitoring Board confirmed that IMP321 is safe and well tolerated
finance.yahoo.com - December 30 at 9:13 AM
nasdaq.com logoMid-Day Market Update: Prima BioMed Climbs Following Positive IMP321 Data; Interpace Diagnostics Shares Slide
www.nasdaq.com - December 30 at 12:05 AM
rttnews.com logoINNL Bleeds Over Dashed Hopes, CRBP To Report Data In Q1, FDA Snubs CEMP
www.rttnews.com - December 30 at 12:05 AM
publicnow.com logoPrima BioMed announces First Clinical Data from Combination of IMP321 with ANTI-PD1
us.rd.yahoo.com - December 29 at 9:14 AM
streetinsider.com logoPrima BioMed (PBMD) Announces Interim Data From IMP321 ... - StreetInsider.com
www.streetinsider.com - December 22 at 12:59 AM
streetinsider.com logoPrima BioMed (PBMD) Announces Interim Data From IMP321 AIPAC Trial
www.streetinsider.com - December 21 at 7:58 PM
us.rd.yahoo.com logo4:36 pm Prima Biomed announces interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer; initial data confirms previous trial results showing IMP321 is safe and well tolerated
us.rd.yahoo.com - December 21 at 7:58 PM

Social

Chart

Prima BioMed Ltd (PBMD) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff